Try Claude
Lead FinderFind & enrich companies and people
AI Tools for Pharmaceutical Researchers
AI tools that help pharmaceutical researchers search the drug discovery literature, look up compound and drug data, monitor clinical trials, find research grants, and compile drug development intelligence reports.
Get started for free
Works in Chat, Cowork and Code
Papers Found
63 publications · PubMed + bioRxiv · 2021–2024
Top Venue
J. Med. Chem. · 22 articles · highest citation count
Key Theme
Ternary complex modeling and E3 ligase selectivity dominant topics
Emerging Area
Molecular glues as PROTAC alternatives — 11 papers 2023–2024
Drug discovery literature search
Search millions of peer-reviewed papers in medicinal chemistry, pharmacology, toxicology, and drug discovery. Find target validation studies, mechanism-of-action papers, SAR analyses, and ADMET research to build the evidence base for new programs.
Find the top papers on covalent inhibitor design and selectivity profiling in targeted covalent drug discovery published since 2021.
Found 28 papers. Top result: "Covalent fragment screening and selectivity optimization for cysteine-targeted inhibitors" (J. Med. Chem., 2023, 387 citations). Returns journal, DOI, target class, and key selectivity data for each.
ToolRouter search_papers
Papers Found
28 papers · cysteine-targeted covalent inhibitors
Top Paper
"Covalent fragment screening and selectivity optimization" J. Med. Chem. 2023 · 387 citations
Key Theme
Selectivity profiling by chemo-proteomics becoming standard
Emerging Topic
Non-cysteine electrophilic warheads gaining attention
Clinical pipeline monitoring
Track competitor drug pipelines by searching ClinicalTrials.gov for trials by target, indication, mechanism, or sponsor. Monitor Phase 1-3 progress, trial design choices, and primary endpoint selections across therapeutic areas.
Find all active Phase 1 and Phase 2 trials for antibody-drug conjugates (ADCs) in solid tumors targeting HER2 or TROP-2 recruiting in 2024.
Found 22 trials. Notable new entrants: FS-1502 (HER2 ADC, Phase 1, novel linker-payload), ABBV-CLS-484 + SYD985 combination (Phase 1b), datopotamab deruxtecan TROP-2 expansion (Phase 3). Includes sponsor, NCT number, endpoints, and dosing schedule.
ToolRouter search_trials
DrugTargetPhase
FS-1502HER2Phase 1
ABBV-CLS-484 + SYD985HER2 comboPhase 1b
Dato-DXd (TROP-2)TROP-2Phase 3
SKB264TROP-2Phase 2
22 active trials · HER2 + TROP-2 solid tumors
Compound and drug database lookups
Look up chemical structures, physicochemical properties (logP, MW, PSA, solubility), and CAS numbers for drug candidates, approved drugs, and reference compounds. Essential for lead optimization, formulation development, and ADMET assessment.
Get the molecular formula, MW, cLogP, PSA, rotatable bonds, and aqueous solubility for venetoclax as a reference for BCL-2 inhibitor lead optimization.
Venetoclax (ABT-199): MW 868.44 g/mol, cLogP 9.6, PSA 170 Ų, 13 rotatable bonds, aqueous solubility ~0.002 mg/mL. High MW/cLogP challenge — overcame with amorphous solid dispersion formulation. HBD: 2, HBA: 10. CAS: 1257044-40-8.
ToolRouter get_compound
PropertyValueNote
Molecular Weight868.44 g/molHigh MW — amorphous solid dispersion formulation
cLogP9.6High lipophilicity — formulation challenge
PSA170 ŲHigh — oral absorption by dispersed formulation
Aqueous Solubility~0.002 mg/mLVery low — requires solubilizing excipients
CAS 1257044-40-8 · BCL-2 selective inhibitor
Approved drug landscape analysis
Retrieve FDA-approved drug labeling for competitor drugs, mechanism references, and predecessor molecules. Analyze approved drug efficacy endpoints, safety profiles, and labeling language for NDA positioning and differentiation strategy.
Get FDA labeling for trastuzumab deruxtecan (Enhertu) including HER2 threshold for approval, response rates, key adverse effects, and dosing for use as a competitive benchmark.
T-DXd: HER2+ (IHC 3+ or ISH+) NSCLC and breast cancer. Key efficacy: DESTINY-Breast04 ORR 52.3% vs 16.3% TPC in HER2-low. DLT: interstitial lung disease (10-15% incidence) — key differentiator risk vs competitor ADCs. Dose: 5.4 mg/kg IV q3 weeks.
ToolRouter get_drug
HER2 Threshold
IHC 3+ or ISH+ · also HER2-low IHC 1+ or 2+/ISH-
Key Efficacy
DESTINY-Breast04: ORR 52.3% vs 16.3% TPC in HER2-low
Key Safety
ILD 10–15% incidence — key differentiation risk vs competitors
Dosing
5.4 mg/kg IV every 3 weeks
Competitive landscape intelligence
Compile comprehensive reports on any drug class, disease indication, or biological target. Pull together the approved drug landscape, clinical pipeline, and preclinical literature to build competitive intelligence for portfolio decisions.
Compile a competitive intelligence report on the IL-17A inhibitor market — approved drugs, clinical pipeline, mechanism variations, and differentiating efficacy and safety data.
Compiled 24-source report: secukinumab and ixekizumab dominate with full IL-17A blockade; bimekizumab (IL-17A/F dual) shows superior psoriasis clearance (PASI 90 ~80%); IL-17RA inhibitor brodalumab carries black box for suicidality; emerging: anti-IL-17A bispecifics in early development. Pipeline shows 4 Phase 2 candidates.
ToolRouter research
Market Leaders
Secukinumab + ixekizumab (full IL-17A blockade) dominate
Best-in-Class
Bimekizumab (IL-17A/F dual): PASI 90 ~80% vs ~60% secukinumab
Safety Signal
Brodalumab (IL-17RA): black box suicidality warning
Pipeline
4 Phase 2 anti-IL-17A bispecifics in early development
Research grant funding for drug discovery
Find NIH, pharmaceutical foundation, and technology transfer grant opportunities for academic drug discovery and target validation research. Identify the right mechanism and deadline for your research program.
Find NIH and private foundation grants for academic researchers conducting target validation and early drug discovery for rare diseases.
Found 6 opportunities: NIH National Center for Advancing Translational Sciences (NCATS) TRND program (rolling), NCATS Rare Diseases Research grant (April 5), TargetALS research grant (quarterly, up to $150K), Rare Cancer Research Foundation (June 30). Includes eligibility, amount, and application links.
ToolRouter search_grants
FunderProgramAmount
NIH NCATSTRND — target validationUp to $2M
NIH NCATSRare Diseases ResearchUp to $500K
TargetALSResearch grantUp to $150K
Rare Cancer Research FoundationInvestigator awardUp to $100K
6 opportunities identified · eligibility and links included
Ready-to-use prompts
Literature search
Find the top 15 papers on blood-brain barrier penetration strategies for CNS drug delivery including exosome, nanoparticle, and antibody-based approaches published since 2021.
Clinical pipeline search
Find all active Phase 2 and 3 clinical trials for oral GLP-1 receptor agonists for type 2 diabetes and obesity. Include sponsor, compound name, and primary endpoints.
Compound properties
Look up the physicochemical properties (MW, cLogP, PSA, solubility, pKa) and CAS number for imatinib and dasatinib for Bcr-Abl inhibitor reference comparison.
Drug labeling lookup
Get FDA labeling for pembrolizumab (Keytruda) including all approved indications, PD-L1 biomarker thresholds by indication, dosing, and key immune-related adverse events.
Competitive landscape
Research the competitive landscape for CDK4/6 inhibitors — approved drugs, differentiated safety profiles, combination strategies, and emerging resistance mechanisms and next-generation compounds.
Grant search
Find NIH R01 and R21 grants for pharmaceutical researchers studying novel drug delivery systems or targeted therapy mechanisms in oncology. Include upcoming deadlines.
Drug mechanism diagram
Draw a labeled diagram of the mechanisms of action of CDK4/6 inhibitors showing cyclin D-CDK4/6 complex inhibition, Rb dephosphorylation, and G1/S cell cycle arrest.
Find collaborators
Find medicinal chemists and pharmacologists at pharmaceutical research institutes and biotech companies in the US and Europe working on targeted protein degradation.
Tools to power your best work
Academic ResearchSearch papers, authors, citations
Deep ResearchAI research reports with citations
Drug InformationDrug info: recalls & side effects
Diagram GeneratorRender Mermaid, PlantUML & more
Chemistry LookupCompounds, elements, and safety
Clinical TrialsClinical trials & drug safety data
Grants FinderFind grants, funding fits, and precedent
165+ tools.
One conversation.
Everything pharmaceutical researchers need from AI, connected to the assistant you already use. No extra apps, no switching tabs.
Target-to-hit research package
Build a comprehensive evidence package for a new drug target covering biology, published inhibitor data, and competitive clinical pipeline.
Lead optimization reference building
Gather physicochemical and pharmacological reference data for lead series optimization, comparing against approved drugs in the class.
NDA positioning and differentiation
Prepare for NDA filing by analyzing the competitive drug landscape, labeling language, and clinical endpoint precedents in the indication.
Frequently Asked Questions
Can Academic Research cover medicinal chemistry journals specifically?
Academic Research indexes publications from major medicinal chemistry and pharmacology journals including Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics, ACS Medicinal Chemistry Letters, and Drug Discovery Today.
Does Chemistry Lookup provide ADMET-relevant data for drug compounds?
Chemistry Lookup provides physicochemical properties relevant to ADMET prediction (MW, cLogP, PSA, HBD/HBA counts, rotatable bonds) for well-characterized compounds. Measured ADMET data (Caco-2, hERG binding, hepatocyte stability) is better found in specialized ADMET databases or the primary literature via Academic Research.
How comprehensive is the Drug Information coverage for new approvals?
Drug Information covers the FDA drug label database, which is updated with new approvals. Products approved in the last 1-3 months may have a short lag before labeling appears in the database.
Can I use Clinical Trials to track competitor early-phase programs?
Phase 1 trials are required to register on ClinicalTrials.gov before first patient enrollment. The Clinical Trials tool can retrieve these registrations, though early-phase sponsor data may be limited. Some sponsors include minimal information at Phase 1 registration.
Can Deep Research compile indication-specific drug approval histories?
Yes. Deep Research can synthesize FDA approval histories, key trial data, and regulatory milestones for specific drug classes or indications from publicly available sources including FDA approval packages, press releases, and published review articles.
Give your AI superpowers.
Get started for free
Works in Chat, Cowork and Code